About Us

MindRank is a clinical stage AI-powered drug discovery company.

Our Mission

To transform drug discovery and development by continuously inventing and integrating innovations across machine learning, biology and chemistry. Our ultimate goal is to find better drugs, treat more diseases, and help more patients.

Focusing on Hard-to-Drug Molecular Targets

In addition to speeding up and reducing costs of drug discovery, we aim to discover innovative therapies and increase the overall drug R&D successful rate.

Our Journey

2021
Our former AI solution was selected for funding (multi-million EURO) by the 2020 "Europe Innovative Medicines Initiative" to combat coronavirus
Mar
Our proprietary AI solution was nominated by Deep Pharma Intelligence as one of the 11 "Top AI Breakthroughs in Biopharma from 2018 to 2020"
May
Raised $7M Seed Funding from Sherpa Healthcare Partners
Jun
The AI team won 1st place in the "Global Artificial Intelligence Technology Innovation Contest" hosted in Hangzhou, China
Jul
Delivered an allosteric inhibitor PCC with Best-in-Class potential to a public traded biotech company
Aug
Partnership with Antengene (6996.HK) on AI-enabled Drug Discovery
Oct
Partnership with Medicilon (SHA:688202) on AI-enabled Drug Discovery
Dec
Tens of millions US dollar Series A Funding
2022

Jan
- AI drug discovery paper published in Nature Biomedical Engineering
- Partnership with Chemexpress (SHA:688131) strengthened in AI-enabled Synthetic Accessibility
- Mindrank's AI-designed proprietary small molecule drug began IND-enabling studies, eight months after program initiation
Jul
Successfully delivered 4 drug discovery projects
Dec
Won the 4th China Health Innovation Platform Award
Dec
US IND Approval for Mindrank's AI-designed proprietary small molecule GLP-1 RA MDR-001
2023

Jan
Awarded the 2022 Venture50 award by Zero2IPO Group and Pedaily
Apr
China CDE Approval for Mindrank's AI-designed proprietary small molecule GLP-1 RA MDR-001
Jun
Completed the first healthy volunteer dosed in the Phase I study of MDR-001
Jul
Secured $23M in Series A+ Funding
Aug
- Pan-European collaborative project secured funding from the Dynamic Resilience program, launched by Wellcome Leap and Temasek Trust
- Recognized as one of the "100 to Watch" in Forbes Asia's 2023 list
Sep
Completed the dosing of first cohort in Phase II study of MDR-001
Nov
- Started conducting IND-enabling studies for our “first-in-class” preclinical candidate MRANK-106
- Initiated the IND-enabling studies for our preclinical candidate MRANK-108, which has the potential to become the best-in-class candidate
2024